Search Results

Tricol Biomedical, a global leader in innovating hemostasis and wound care solutions, has expanded its GPO agreements with Premier, Inc. and Vizient® to include the OneStop™ Vascular line of procedural care products.

The US Patent and Trademark Office has granted Tricol Biomedical, a global leader in innovating hemostasis and wound care solutions, a new patent (#11,564,673) for the company’s modified chitosan dressing and its through-the-scope delivery in the gastrointestinal (GI) tract to quickly control serious bleeding for up to 96 hours.

A preclinical study presented at the Military Health System Research Symposium this month demonstrated that the proprietary† Absorbable Biocompatible Chitosan investigational product from Tricol Biomedical is both absorbable and biocompatible in an internal bleeding rodent model.